On November 22, 2013, the US Food and Drug Administration (FDA) effectively halted health-related direct-to-consumer genetic testing in the United States by sending a warning letter to 23andMe, the leading company in the field, directing it to stop providing such testing.1 The FDA acted as the era of widespread, clinical use of DNA sequencing rapidly approaches. The agency’s action will contribute to changes in which genetic tests are offered to patients and how testing is provided.
Zettler PJ, Sherkow JS, Greely HT. 23andMe, the Food and Drug Administration, and the Future of Genetic Testing. JAMA Intern Med. 2014;174(4):493–494. doi:10.1001/jamainternmed.2013.14706